Oct 1 |
Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting
|
Sep 27 |
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
|
Sep 24 |
Savara appoints Braden Parker as Chief Commercial Officer
|
Sep 24 |
Savara Appoints Braden Parker as Chief Commercial Officer, Effective Immediately
|
Sep 23 |
Savara to Host Analyst and Investor Webinar on September 30, 2024
|
Sep 9 |
Savara: Trial Successful, But I'm Only Half Convinced
|
Sep 9 |
Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
|
Sep 8 |
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
|
Sep 5 |
Exploring Grid Dynamics Holdings And Two High Growth Tech Stocks
|
Sep 3 |
Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|